SCHEMBL4765788

SCHEMBL4765788

CCN1CCN(c2nc(-c3cc(F)c(OCCF)c(F)c3)cc3ccccc23)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.42
KMT2A Q03164 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.40
CYP2D6 P10635 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
SCN9A Q15858 1/20 0.39
TSHR P16473 3/20 0.38
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
PKN2 Q16513 1/20 0.38
HTT P42858 3/20 0.38
HRH4 Q9H3N8 1/20 0.38
HPGD P15428 3/20 0.37
GBA1 P04062 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4766579 0.99 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19
SCHEMBL4764182 0.94 SMN1; SMN2 (0.42) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19
SCHEMBL4766438 0.91 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL4770039 0.90 KMT2A (0.41) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19
Oxalic Acid SCHEMBL4766826 0.90 KDM4E (0.42) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19
SCHEMBL6292068 0.88 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19
SCHEMBL4766177 0.87 PRMT5 (0.46) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19
SCHEMBL4767474 0.86 SMN1; SMN2 (0.38) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19
SCHEMBL4772825 0.86 RAB9A (0.45) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL4773346 0.85 RAB9A (0.45) SMN1; SMN2KMT2AL3MBTL1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US claimed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP claimed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 SMN1; SMN2 27/4885KMT2A 1240/4885L3MBTL1 4124/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 SMN1; SMN2 37/4885KMT2A 1300/4885L3MBTL1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.